EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Challenges and Prospects of Patient-Derived Xenografts for Cancer Research

Jiankang Jin iD, Katsuhiro Yoshimura, Matheus Sewastjanow-Silva iD, Shumei Song, Jaffer A Ajani

Cancers · 31.08.2023 · 15 (17) · 4352

DOI: 10.3390/cancers15174352 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.08.2023. Verfasst von Jiankang Jin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Department of Defense, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its progression, similar to human tumors, are particularly common. The standard procedures and rationales of gastric adenocarcinoma (GAC) orthotopic models are addressed. Despite the significant advantages of the PDX models, such as recapitulating key features of human tumors and enabling drug testing in the in vivo context, some challenges must be acknowledged, including loss of heterogeneity, selection bias, clonal evolution, stroma replacement, tumor micro-environment (TME) changes, host cell carryover and contaminations, human-to-host cell oncogenic transformation, human and host viral infections, as well as limitations for immunologic research. To compensate for these limitations, other mouse models, such as syngeneic and humanized mouse models, are currently utilized. Overall, the PDX models represent a powerful tool in cancer research, providing critical insights into tumor biology and potential therapeutic targets, but their limitations and challenges must be carefully considered for their effective use. Lastly, we present an intronic quantitative PCR (qPCR) method to authenticate, detect, and quantify human/murine cells in cell lines and PDX samples.

Schlagwörter

Stichwörter der Autor:innen

authentication and quantification of biosampleshumanized mice (HM)intronic quantitative PCR (qPCR)orthotopic PDX (PODX)patient-derived xenograft (PDX)tumor microenvironment (TME)

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Jiankang Jin, Matheus Sewastjanow-Silva

Förderung

  • NCI NIH HHS
  • Department of Defense
  • National Institutes of Health
  • Caporella family
  • Park family
  • Dallas family
  • Dio family
  • Frankel family

Zitieren

APA

Jin, J., Yoshimura, K., Sewastjanow-Silva, M., Song, S., & Ajani, J. A. (2023). Challenges and Prospects of Patient-Derived Xenografts for Cancer Research. Cancers, 15(17), 4352. https://doi.org/10.3390/cancers15174352

Vancouver

Jin J, Yoshimura K, Sewastjanow-Silva M, Song S, Ajani JA. Challenges and Prospects of Patient-Derived Xenografts for Cancer Research. Cancers. 2023;15(17):4352. doi:10.3390/cancers15174352

BibTeX
@article{Jin2023,
  author = {Jin, Jiankang and Yoshimura, Katsuhiro and Sewastjanow-Silva, Matheus and Song, Shumei and Ajani, Jaffer A},
  title = {Challenges and Prospects of Patient-Derived Xenografts for Cancer Research},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {17},
  pages = {4352},
  doi = {10.3390/cancers15174352}
}
Kostenlos starten →